GW Pharmaceuticals is a British biopharmaceutical company known for its multiple sclerosis treatment product Sativex, nabiximols (brand name, Sativex). Sativex is the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, for treatment of epilepsy, underwent phase 3 clinical trials in 2015.

Property Value
dbo:abstract
  • GW Pharmaceuticals est une laboratoire pharmaceutique britannique, fondée en 1998 et coté en bourse au NASDAQ Global Market (GWPH) et à l'AIM sur le marché London Stock Exchange. Le laboratoire dispose d'une autorisation en Angleterre pour le développement de médicaments basé sur la médecine des cannabinoïdes. (fr)
  • GW Pharmaceuticals is a British biopharmaceutical company known for its multiple sclerosis treatment product Sativex, nabiximols (brand name, Sativex). Sativex is the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, for treatment of epilepsy, underwent phase 3 clinical trials in 2015. (en)
dbo:foundingYear
  • 1998-01-01 (xsd:date)
dbo:location
dbo:revenue
  • 3.38E7
dbo:type
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 36476338 (xsd:integer)
dbo:wikiPageRevisionID
  • 738861502 (xsd:integer)
dbp:divisions
  • Biotechnology
dbp:founder
  • Geoffrey Guy and Brian Whittle
dbp:industry
  • Pharmaceutical
dbp:keyPeople
  • Justin Gover
dbp:locationCountry
  • United Kingdom
dbp:products
  • Sativex®
dct:subject
http://purl.org/linguistics/gold/hypernym
rdf:type
rdfs:comment
  • GW Pharmaceuticals est une laboratoire pharmaceutique britannique, fondée en 1998 et coté en bourse au NASDAQ Global Market (GWPH) et à l'AIM sur le marché London Stock Exchange. Le laboratoire dispose d'une autorisation en Angleterre pour le développement de médicaments basé sur la médecine des cannabinoïdes. (fr)
  • GW Pharmaceuticals is a British biopharmaceutical company known for its multiple sclerosis treatment product Sativex, nabiximols (brand name, Sativex). Sativex is the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, for treatment of epilepsy, underwent phase 3 clinical trials in 2015. (en)
rdfs:label
  • GW Pharmaceuticals (fr)
  • GW Pharmaceuticals (en)
owl:sameAs
prov:wasDerivedFrom
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • GW Pharmaceuticals PLC (en)
is dbo:wikiPageRedirects of
is foaf:primaryTopic of